Search Thermo Fisher Scientific

Primary Antibodies

Order Status

Quick Order

Sign in
Sign in

Don't have an account ? Create Account

Loading ...

Invitrogen

SIGLEC15 Polyclonal Antibody

8 Published Figures

View all (9) SIGLEC15 antibodies

Questions & Answers

Questions & Answers

Antibody Testing Data (1)
Published Figures (8)

Application

SIGLEC15 Antibody in Immunohistochemistry (Paraffin) (IHC (P))

FIGURE: 1 / 9

SIGLEC15 Antibody (PA5-50759) in IHC (P)

Immunohistochemical analysis of SIGLEC15 inparaffin-embedded Human liver cancer tissue using SIGLEC15 Polyclonal Antibody (Product # PA5-50759) at a 1:50 dilution. (Original magnification: x200).

SIGLEC15 Antibody in Immunohistochemistry (Paraffin) (IHC (P))

SIGLEC15 Antibody in Western Blot, Immunocytochemistry (WB, ICC/IF)

SIGLEC15 Antibody in Western Blot, Immunocytochemistry (WB, ICC/IF)

SIGLEC15 Antibody in Western Blot, Immunohistochemistry (WB, IHC)

SIGLEC15 Antibody in Western Blot (WB)

SIGLEC15 Antibody in Western Blot (WB)

SIGLEC15 Antibody in Western Blot (WB)

SIGLEC15 Antibody in Western Blot (WB)

SIGLEC15 Antibody in Western Blot (WB)

Product Image Gallery

SIGLEC15 Antibody in Immunohistochemistry (Paraffin) (IHC (P)) — Immunohistochemical analysis of SIGLEC15 inparaffin-embedded Human liver cancer tissue using SIGLEC15 Polyclonal Antibody (Product # PA5-50759) at a 1:50 dilution. (Original magnification: x200).

SIGLEC15 Antibody in Western Blot, Immunocytochemistry (WB, ICC/IF) — 4 FIGURE Siglec-15 was a direct target of miR-7109 in clear-cell renal cell carcinoma (ccRCC). (A) Real-time PCR analysis of miR-7109 expression in ccRCC tumor samples with paired adjacent normal tissues. (B) Correlation analysis between miR-7109 and Siglec-15 in ccRCC tissue samples (n = 100). (C) Change of miR-7109 expression in both A704 and A498 cells in response to miR-7109 inhibitor. (D) Change of miR-7109 expression in both 769-p and Caki-1 cells in response to miR-7109 mimic. (E) Endogenous Siglec-15 transcripts were quantified in both A704 and A498 cells transfected with either control or miR-7109 inhibitor. (F) Endogenous Siglec-15 transcripts were quantified in both 769-p and Caki-1 cells transfected with either control or miR-7109 mimics. (G) Western blot analysis of Siglec-15 proteins in the same cells as in panel E and F. (H) Flow cytometry analysis of cell surface Siglec-15 abundance in A704 and A498 cells in response to miR-7109 inhibitor. (I) Flow cytometry analysis of cell surface Siglec-15 abundance in 769-p and Caki-1 cells in response to miR-7109 mimics. (J) Immunofluorescence staining of cell surface Siglec-15 in A498 cells transfected with either control or miR-7109 inhibitor. (K) Alignment between miR-7109 seed region and both wild-type and putative binding site-mutated Siglec-15 3'UTR. (L) Luciferase reporter analysis of the potential regulatory effects of miR-7109 on Siglec-15 in 293T cells, which were transfected with control, miR-7109 mimics, and m

SIGLEC15 Antibody in Western Blot, Immunocytochemistry (WB, ICC/IF) — 3 FIGURE LINC00973-upregulated Siglec-15 was dependent on miR-7109. (A) Real-time PCR analysis of endogenous miR-7109 in LINC00973-deficient 769-p and Caki-1 cells in response to either negative control or miR-7109 inhibitor. (B) Real-time PCR analysis of endogenous miR-7109 in LINC00973-proficient A704 and A498 cells in response to either control or miR-7901 mimic. (C) Quantitative analysis of Siglec-15 transcript in LINC00973 intact or depleted 769-p and Caki-1 cells treated with control or miR-7109 inhibitor. (D) Quantitative analysis of Siglec-15 transcript in LINC00973 naive or overexpressing A704 and A498 cells treated with control or miR-7109 mimics. (E) Western blot results of Siglec-15 protein in the cells as described in C and D. (F) Immunofluorescence staining of cell surface Siglec-15 in A498 cells expressing either naive or ectopic LINC00973, and transfected with either control or miR-7109 mimics. (G, H) Flow cytometry analysis of cell surface abundance of Siglec-15 in cells as specified in panel E

SIGLEC15 Antibody in Western Blot, Immunohistochemistry (WB, IHC) — 2 FIGURE LINC00973 upregulated Siglec-15 in clear-cell renal cell carcinoma (ccRCC) cells. (A) Comparison of LINC00973 abundance in Siglec-15 negative and positive ccRCC tumors. (B) Representative images of Siglec-15 immunohistochemistry (IHC) staining results. (C) Correlation analysis of endogenous LINC00973 and Siglec-15 expression in publicly available TCGA kidney cells (n = 34). (D) Correlation analysis of LINC00973 and Siglec-15 in clinical ccRCC tumor samples (n = 100). (E) Establishment of LINC00973-knockdown cell lines in 769-p and Caki-1 cells was validated by real-time PCR. (F) Establishment of LINC00973-overexpressing cell lines in A704 and A498 cells was validated by real-time PCR. (G) Relative expression of Siglec-15 transcripts in LINC00973-deficient 769-p and Caki-1 cells. (H). Relative expression of Siglec-15 transcripts in LINC00973-proficient A704 and A498 cells. (I) Western blot analysis of Siglec-15 protein in LINC00973 knockdown or overexpressing cells. Flow cytometry analysis of cell surface Siglec-15 abundance in response to LINC00973 knockdown in 769-p (J) and Caki-1 (K) cells, and LINC00973-overexpressing in A704 (L) and A498 (M). N. Immunofluorescence staining of cell surface Siglec-15 of A498 in response to either control (NC) or LINC00973 overexpression

SIGLEC15 Antibody in Western Blot (WB) — Fig. 6 BACH1-IT2-miR-4786-Siglec-15 axis involved in immune activations in bladder cancer cells. A Establishment of Siglec-15 knockdown cells in UMUC-3 and T24 was confirmed by real-time PCR. B Establishment of Siglec-15 overexpression cells in HT1197 and SW780 cells was confirmed by real-time PCR. C Western blot results of relative expression of Siglec-15 protein in cells described in A and B, and the croppted blots were presented correspondingly. D Interleukin-2 (IL-2) production analysis in Jurkat: UMUC-3/T24 (shNT or shSiglec-15, 2:1) co-culture system. IL-2 was quantified with an ELISA kit at 48 and 72 h, respectively. E IL-2 production analysis in Jurkat: HT1197/SW780 (EV or Siglec-15, 2:1) co-culture system. F IL-2 production analysis of Jurkat co-culture system with both HT1197 and SW780 cells transfected with control or BACH1-IT2 in combination with either miR-NC or miR4786 mimics. G IL-2 production analysis of Jurkat co-culture system with both UMUC-3 and T24 cells transfected with negative control or shBACH1-IT2 in combination with either miR-NC or miR-4786 inhibitor. H Tumor necrosis factor-alpha (TNF-alpha) secretion analysis of Jurkat co-culture system with both UMUC-3 and T24 cells transfected with negative control or shBACH1-IT2 in combination with either miR-NC or miR-4786 inhibitors. I TNF-alpha secretion analysis of Jurkat co-culture system with both HT1197 and SW780 cells transfected with either control or BACH1-IT2 in combination with either miR-NC or miR

SIGLEC15 Antibody in Western Blot (WB) — Siglec-15 was a direct target of miR-4786 in bladder cancer. A Real-time PCR analysis of miR-4786 expression in bladder tumor samples with paired adjacent normal tissues. B Correlation analysis between miR-4786 and Siglec-15 in bladder tumors ( n = 100). C Change of miR-4786 expression in both HT1197 and SW780 cells in response to miR-4786 inhibitor (upper) and Siglec-15 was determined accordingly (lower). D Change of miR-4786 expression in both UMUC-3 and T24 cells in response to miR-4786 mimic (upper) and Siglec-15 was determined accordingly (lower). E Western blot analysis of Siglec-15 proteins in UMUC3 and T24 cells transfected with either control or miR-4786 mimic (left), as well as HT1197 and SW780 cells transfected with either negative control (miR-NC) or miR-4786-specific inhibitor (right), and the croppted blots were presented correspondingly. F Immunofluorescence staining of cell surface Siglec-15 in HT1197 cells transfected with either control or miR-4786 inhibitor. G Alignment between miR-4786 seed region and both wild-type and putative binding site-mutated Siglec-15 3'UTR. H Luciferase reporter analysis of the potential regulatory effects of miR-4786 on Siglec-15 in 293 T cells, which were transfected with control, miR-4786 mimics, and miR-4786 inhibitors, respectively

SIGLEC15 Antibody in Western Blot (WB) — Fig. 2 BACH1-IT2 upregulated Siglec-15 in bladder cancer cells. A Comparison of BACH1-IT2 abundance in Siglec-15 negative and positive bladder tumors. B Representative images of Siglec-15 immunohistochemistry (IHC) staining results. C Correlation between endogenous BACH1-IT2 and Siglec-15expression in bladder tumors. D Establishment of BACH1-IT2-knockdown cell lines in UMUC-3 and T24 cells was validated by real-time PCR (upper pane) and according Siglec-15 was quantified (lower pane). E Establishment of BACH1-IT2-overexpressing cell lines in HT1197 and SW780 cells was validated by real-time PCR and according Siglec-15 was quantified (lower pane). F Western blot analysis of Siglec-15 protein in BACH1-IT2 knockdown or overexpressing cells, and the croppted blots were presented correspondingly. G Immunofluorescence staining of cell surface Siglec-15 of HT1197 in response to either control (NC) or BACH1-IT2 overexpression

SIGLEC15 Antibody in Western Blot (WB) — Fig. 3 BACH1-IT2-upregulated Siglec-15 was dependent on miR-4786. A Quantitative analysis of Siglec-15 transcript in BACH1-IT2 intact or depleted UMUC-3 and T24 cells treated with control or miR-4786 inhibitor. Endogenous miR-4786 was quantified accordingly (upper left pane). B Quantitative analysis of Siglec-15 transcript in BACH1-IT2 naive or overexpressing HT1197 and SW780 cells treated with control or miR-4786 mimics. Endogenous miR-4786 was quantified accordingly (upper left pane). C Western blot results of Siglec-15 protein in the cells as described in A and B, and the croppted blots were presented correspondingly. D Immunofluorescence staining of cell surface Siglec-15 in HT1197 cells expressing either naive or ectopic BACH1-IT2, and transfected with either control or miR-4786 mimics

SIGLEC15 Antibody in Western Blot (WB) — 6 FIGURE LINC00973-miR-7109-Siglec-15 axis involved in immune activations in clear-cell renal cell carcinoma (ccRCC) cells. (A) Establishment of Siglec-15 overexpression cells in A704 and A498 was confirmed by real-time PCR. (B) Establishment of Siglec-15 knockdown cells in 769-p and Caki-1 cells was confirmed by real-time PCR. (C) Western blot results of relative expression of Siglec-15 protein in cells described in (A) and (B). (D) Interleukin-2 (IL-2) production analysis in Jurkat: A704/A498 (EV or Siglec-15, 2:1) co-culture system. IL-2 was quantified with an ELISA kit at 48 and 72 h, respectively. (E) IL-2 production analysis in Jurkat: 769-p/Caki-1 (shNT or shSiglec-15, 2:1) co-culture system. (F) IL-2 production analysis of Jurkat co-culture system with both A704 and A498 cells transfected with control or LINC00973 in combination with either miR-NC or miR7109 mimics. (G) IL-2 production analysis of Jurkat co-culture system with both 769-p and Caki-1 cells transfected with negative control or shLINC0973 in combination with either miR-NC or miR-7109 inhibitor. (H) Tumor necrosis factor-alpha (TNF-alpha) secretion analysis of Jurkat co-culture system with both A704 and A498 cells transfected with control or LINC00973 in combination with either miR-NC or miR-7109 mimics. (I) TNF-alpha secretion analysis of Jurkat co-culture system with both 769-p and Caki-1 cells transfected with either negative control or shLINC00973 in combination with either miR-NC or miR-7109 inhibitor

Product Details

PA5-50759

Applications

Tested Dilution

Publications

Western Blot (WB)

1:500-1:2,000

View 2 publications 2 publications

Immunohistochemistry (IHC)

-

View 1 publication 1 publication

Immunohistochemistry (Paraffin) (IHC (P))

1:50-1:200

-

Immunocytochemistry (ICC/IF)

-

View 1 publication 1 publication

Product Specifications

Species Reactivity

Human, Mouse

Published species

Human

Host/Isotype

Rabbit / IgG

Class

Polyclonal

Type

Antibody

Immunogen

Synthetic peptide corresponding to a region derived from internal residues of human sialic acid binding Ig-like lectin 15

Conjugate

Unconjugated

Form

Liquid

Concentration

0.9 mg/mL

Purification

Antigen affinity chromatography

Storage buffer

PBS, pH 7.4, with 40% glycerol

Contains

0.05% sodium azide

Storage conditions

-20°C

Shipping conditions

Ambient (domestic); Wet ice (international)

AB_2636211

Product Specific Information

The antibody detects endogenous levels of total SIGLEC15 protein.

Target Information

Binds sialylated glycoproteins.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.

Product References

Identification of BACH1-IT2-miR-4786-Siglec-15 immune suppressive axis in bladder cancer.

BMC cancer

Li X,Liang Z,Pan J,Zhang M,Liu J,Hu R,Liao C

Published figure using SIGLEC15 polyclonal antibody (Product # PA5-50759) in Western Blot

Mon Mar 11 00:00:00 UTC 2024

LINC00973 is involved in cancer immune suppression through positive regulation of Siglec-15 in clear-cell renal cell carcinoma.

Cancer science

Liu Y,Li X,Zhang C,Zhang H,Huang Y

Published figure using SIGLEC15 polyclonal antibody (Product # PA5-50759) in Immunocytochemistry

Thu Oct 01 00:00:00 UTC 2020

LINC00973 is involved in cancer immune suppression through positive regulation of Siglec-15 in clear-cell renal cell carcinoma.

Cancer science

Liu Y,Li X,Zhang C,Zhang H,Huang Y

Published figure using SIGLEC15 polyclonal antibody (Product # PA5-50759) in Immunocytochemistry

Thu Oct 01 00:00:00 UTC 2020

LINC00973 is involved in cancer immune suppression through positive regulation of Siglec-15 in clear-cell renal cell carcinoma.

Cancer science

Liu Y,Li X,Zhang C,Zhang H,Huang Y

Published figure using SIGLEC15 polyclonal antibody (Product # PA5-50759) in Immunocytochemistry

Thu Oct 01 00:00:00 UTC 2020

LINC00973 is involved in cancer immune suppression through positive regulation of Siglec-15 in clear-cell renal cell carcinoma.

Cancer science

Liu Y,Li X,Zhang C,Zhang H,Huang Y

Published figure using SIGLEC15 polyclonal antibody (Product # PA5-50759) in Immunocytochemistry

Thu Oct 01 00:00:00 UTC 2020

LINC00973 is involved in cancer immune suppression through positive regulation of Siglec-15 in clear-cell renal cell carcinoma.

Cancer science

Liu Y,Li X,Zhang C,Zhang H,Huang Y

Published figure using SIGLEC15 polyclonal antibody (Product # PA5-50759) in Immunocytochemistry

Thu Oct 01 00:00:00 UTC 2020

Bioinformatics

Protein Aliases: CD33 antigen-like 3; CD33 molecule-like 3; sialic acid binding Ig-like lectin 15; Sialic acid-binding Ig-like lectin 15; Siglec; Siglec 15; Siglec-15

Gene Aliases: CD33L3; EG620235; HsT1361; SIGLEC-15; SIGLEC-I; SIGLEC15

UniProt ID: (Human) Q6ZMC9

Entrez Gene ID: (Human) 284266, (Mouse) 620235

Function(s)

Process(es)

regulation of actin cytoskeleton organization innate immune response regulation of bone resorption cellular response to lipoprotein particle stimulus regulation of osteoclast development

Performance Guarantee

If an Invitrogen™ antibody doesn't perform as described on our website or datasheet,we'll replace the product at no cost to you, or provide you with a credit for a future purchase.*

We're here to help

Get expert recommendations for common problems or connect directly with an on staff expert for technical assistance related to applications, equipment and general product use.

Contact tech support

1x1 image pixel for data collection